Physician profile
Tracy Mcilwean
NPI 1104426584
$4,658.22
in general payments reported to CMS, 2019-2025
31 companies · $22.64 in 2025
The $22.64 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $828 · 2022: $1,360 · 2023: $2,029 · 2024: $419 · 2025: $22.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593 · Travel and Lodging: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.32 |
| Travel and Lodging | $877.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $1,214.14 | 2023 | |
| Relievant Medsystems, INC. | $1,200.98 | 2022-2023 | Intracept |
| Collegium Pharmaceutical, INC. | $297.83 | 2021-2024 | Belbuca, Nucynta |
| Nevro Corp. | $263.93 | 2021-2024 | Senza |
| Abbvie INC. | $259.64 | 2022-2024 | |
| Boston Scientific Corporation | $255.32 | 2021-2025 | Wavewriter Alpha Prime 16, Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.58 | 2022-2024 | Relistor |
| Grt US Holding, INC. | $100.54 | 2021 | |
| Almatica Pharma LLC | $82.42 | 2021 | |
| Forte Bio-Pharma LLC | $77.29 | 2022-2023 | Prolate, Nalocet |
| Lundbeck LLC | $71.72 | 2021-2023 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $64.90 | 2021 | |
| Virtus Pharmaceuticals LLC | $60.83 | 2023-2024 | Levorphanol Tartrate |
| Pfizer INC. | $55.90 | 2021-2024 | |
| Saluda Medical Americas, INC. | $52.74 | 2023-2024 | Evoke Scs, Evoke |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $52.39 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.37 | 2022 | |
| Valinor Pharma, LLC | $40.68 | 2023-2024 | Movantik |
| Fidia Pharma USA INC. | $40.35 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $39.03 | 2021-2023 | Ztlido |
| Biodelivery Sciences International, INC. | $38.99 | 2021 | |
| Averitas Pharma INC. | $31.30 | 2023 | Qutenza |
| Novo Nordisk INC | $27.44 | 2024 | Wegovy |
| Amgen INC. | $26.03 | 2021 | |
| Medtronic, INC. | $23.06 | 2021 | |
| Hikma Pharmaceuticals USA | $21.55 | 2022 | |
| Redhill Biopharma INC. | $21.44 | 2021 | |
| Baudax Bio INC. | $20.44 | 2021 | |
| Allergan, INC. | $14.75 | 2021 | |
| Azurity Pharmaceuticals, INC. | $12.80 | 2023 | Edarbi |
| Vertos Medical, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Mcilwean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.